- Home
- MPLX vs TAK Comparison
MPLX vs TAK Comparison
Compare MPLX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPLX | TAK |
|---|---|---|
| Founded | 2012 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.8B | 56.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MPLX | TAK |
|---|---|---|
| Price | $57.49 | $18.06 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $60.88 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.51% | 2.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.86 | $0.04 |
| Revenue Next Year | $5.65 | $0.92 |
| P/E Ratio | ★ $11.76 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.60 | $12.99 |
| 52 Week High | $59.84 | $18.82 |
Technical Indicators
Market Signals| Indicator | MPLX | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 51.10 |
| Support Level | $50.08 | $17.51 |
| Resistance Level | $59.84 | $18.82 |
| Average True Range (ATR) | 1.00 | 0.25 |
| MACD | -0.22 | -0.08 |
| Stochastic Oscillator | 8.70 | 41.70 |
Price Performance
Historical ComparisonAbout MPLX MPLX LP
MPLX is a partnership that owns pipelines and gathering and processing assets with extensive holdings in the Appalachian and Permian regions. The asset base is made up of crude oil and refined products assets dropped down from Marathon Petroleum, its sponsor, and natural gas and natural gas liquids gathering and processing assets that were purchased or built.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.